vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and COHEN & STEERS, INC. (CNS). Click either name above to swap in a different company.
Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($191.2M vs $143.8M, roughly 1.3× COHEN & STEERS, INC.). On growth, Axsome Therapeutics, Inc. posted the faster year-over-year revenue change (57.4% vs 2.9%). Over the past eight quarters, Axsome Therapeutics, Inc.'s revenue compounded faster (48.1% CAGR vs 8.3%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Cohen & Steers is an American investment management company. It focuses on investments in real estate securities via real estate investment trusts (REIT) and alternative income via preferred securities.
AXSM vs CNS — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $191.2M | $143.8M |
| Net Profit | — | $34.9M |
| Gross Margin | — | — |
| Operating Margin | -33.1% | 28.0% |
| Net Margin | — | 24.3% |
| Revenue YoY | 57.4% | 2.9% |
| Net Profit YoY | — | -23.9% |
| EPS (diluted) | — | $0.67 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $191.2M | — | ||
| Q4 25 | $196.0M | $143.8M | ||
| Q3 25 | $171.0M | $141.7M | ||
| Q2 25 | $150.0M | $136.1M | ||
| Q1 25 | $121.5M | $134.5M | ||
| Q4 24 | $118.8M | $139.8M | ||
| Q3 24 | $104.8M | $133.2M | ||
| Q2 24 | $87.2M | $121.7M |
| Q1 26 | — | — | ||
| Q4 25 | $-28.6M | $34.9M | ||
| Q3 25 | $-47.2M | $41.7M | ||
| Q2 25 | $-48.0M | $36.8M | ||
| Q1 25 | $-59.4M | $39.8M | ||
| Q4 24 | $-74.9M | $45.8M | ||
| Q3 24 | $-64.6M | $39.7M | ||
| Q2 24 | $-79.3M | $31.8M |
| Q1 26 | -33.1% | — | ||
| Q4 25 | -13.8% | 28.0% | ||
| Q3 25 | -27.0% | 34.5% | ||
| Q2 25 | -24.5% | 31.8% | ||
| Q1 25 | -46.9% | 33.6% | ||
| Q4 24 | -61.1% | 35.3% | ||
| Q3 24 | -59.8% | 33.7% | ||
| Q2 24 | -89.5% | 31.5% |
| Q1 26 | — | — | ||
| Q4 25 | -14.6% | 24.3% | ||
| Q3 25 | -27.6% | 29.4% | ||
| Q2 25 | -32.0% | 27.1% | ||
| Q1 25 | -48.9% | 29.6% | ||
| Q4 24 | -63.1% | 32.8% | ||
| Q3 24 | -61.7% | 29.8% | ||
| Q2 24 | -91.0% | 26.1% |
| Q1 26 | — | — | ||
| Q4 25 | $-0.55 | $0.67 | ||
| Q3 25 | $-0.94 | $0.81 | ||
| Q2 25 | $-0.97 | $0.72 | ||
| Q1 25 | $-1.22 | $0.77 | ||
| Q4 24 | $-1.54 | $0.89 | ||
| Q3 24 | $-1.34 | $0.77 | ||
| Q2 24 | $-1.67 | $0.63 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $305.1M | $145.5M |
| Total DebtLower is stronger | $70.0M | — |
| Stockholders' EquityBook value | — | $562.0M |
| Total Assets | $713.6M | $876.7M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $305.1M | — | ||
| Q4 25 | $322.9M | $145.5M | ||
| Q3 25 | $325.3M | $98.1M | ||
| Q2 25 | $303.0M | $95.4M | ||
| Q1 25 | $300.9M | $65.2M | ||
| Q4 24 | $315.4M | $183.0M | ||
| Q3 24 | $327.3M | $106.5M | ||
| Q2 24 | $315.7M | $122.0M |
| Q1 26 | $70.0M | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | $88.3M | $562.0M | ||
| Q3 25 | $73.7M | $550.3M | ||
| Q2 25 | $73.1M | $528.5M | ||
| Q1 25 | $53.2M | $507.7M | ||
| Q4 24 | $57.0M | $511.7M | ||
| Q3 24 | $92.9M | $491.0M | ||
| Q2 24 | $102.9M | $463.2M |
| Q1 26 | $713.6M | — | ||
| Q4 25 | $689.8M | $876.7M | ||
| Q3 25 | $669.3M | $801.6M | ||
| Q2 25 | $639.8M | $751.0M | ||
| Q1 25 | $596.7M | $834.9M | ||
| Q4 24 | $568.5M | $812.4M | ||
| Q3 24 | $561.5M | $727.8M | ||
| Q2 24 | $548.2M | $784.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-120.4M |
| Free Cash FlowOCF − Capex | — | $-126.4M |
| FCF MarginFCF / Revenue | — | -87.9% |
| Capex IntensityCapex / Revenue | — | 4.2% |
| Cash ConversionOCF / Net Profit | — | -3.45× |
| TTM Free Cash FlowTrailing 4 quarters | — | $-253.6M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $-120.4M | ||
| Q3 25 | $1.0M | $55.1M | ||
| Q2 25 | $-32.4M | $-67.6M | ||
| Q1 25 | $-43.4M | $-108.9M | ||
| Q4 24 | $-26.2M | $96.7M | ||
| Q3 24 | $-18.6M | $25.6M | ||
| Q2 24 | $-30.1M | $31.4M |
| Q1 26 | — | — | ||
| Q4 25 | $-18.7M | $-126.4M | ||
| Q3 25 | $988.0K | $52.6M | ||
| Q2 25 | $-32.4M | $-69.8M | ||
| Q1 25 | $-43.7M | $-110.0M | ||
| Q4 24 | $-26.2M | $85.0M | ||
| Q3 24 | $-18.7M | $24.2M | ||
| Q2 24 | $-30.2M | $27.1M |
| Q1 26 | — | — | ||
| Q4 25 | -9.6% | -87.9% | ||
| Q3 25 | 0.6% | 37.1% | ||
| Q2 25 | -21.6% | -51.3% | ||
| Q1 25 | -36.0% | -81.8% | ||
| Q4 24 | -22.1% | 60.8% | ||
| Q3 24 | -17.9% | 18.2% | ||
| Q2 24 | -34.6% | 22.3% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 4.2% | ||
| Q3 25 | 0.0% | 1.8% | ||
| Q2 25 | 0.0% | 1.6% | ||
| Q1 25 | 0.3% | 0.8% | ||
| Q4 24 | 0.0% | 8.3% | ||
| Q3 24 | 0.1% | 1.1% | ||
| Q2 24 | 0.1% | 3.5% |
| Q1 26 | — | — | ||
| Q4 25 | — | -3.45× | ||
| Q3 25 | — | 1.32× | ||
| Q2 25 | — | -1.84× | ||
| Q1 25 | — | -2.74× | ||
| Q4 24 | — | 2.11× | ||
| Q3 24 | — | 0.65× | ||
| Q2 24 | — | 0.99× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AXSM
| Product sales, net | $189.4M | 99% |
| Royalty revenue and milestone revenue | $1.8M | 1% |
CNS
Segment breakdown not available.
